Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

被引：0
|
作者：
Brian R. Ott
Lesley M. Blake
Ethel Kagan
Malca Resnick
机构：
[1] Rhode Island Hospital – APC 6,The Alzheimer’s Disease & Memory Disorders Center
[2] Northwestern University,Department of Psychiatry
[3] Harborside Financial Center,Forest Laboratories, Inc.
来源：
Journal of Neurology | 2007年 / 254卷
关键词：
Alzheimer’s disease; memantine; open label; randomized controlled trial; ADAS-cog;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 358
页数：7
相关论文
共 50 条
  • [21] The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients
    Zhang, Nan
    Wei, Changjuan
    Du, Hongjian
    Shi, Fu-Dong
    Cheng, Yan
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 40 (1-2) : 85 - 93
  • [22] An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer's Disease
    Gordon, Marc L.
    Christen, Erica
    Keehlisen, Lynda
    Gong, Michelle
    Lam, Fung
    Giliberto, Luca
    Gomar, Jesus J.
    Koppel, Jeremy
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2024, 8 (01) : 1111 - 1114
  • [23] Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Takase, Takao
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 232 - 239
  • [24] Sustained Effects of Once-Daily Memantine Treatment on Cognition and Functional Communication Skills in Patients with Moderate to Severe Alzheimer's Disease: Results of a 16-Week Open-Label Trial
    Schulz, Joerg B.
    Rainer, Michael
    Kluenemann, Hans-Hermann
    Kurz, Alexander
    Wolf, Stefanie
    Sternberg, Kati
    Tennigkeit, Frank
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (03) : 463 - 475
  • [25] Effectiveness and Safety of Donepezil in Hispanic Patients with Alzheimer's Disease: A 12-Week Open-Label Study
    Lopez, Oscar L.
    Mackell, Joan A.
    Sun, Yijun
    Kassalow, Laurent M.
    Xu, Yikang
    McRae, Thomas
    Li, Honglan
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2008, 100 (11) : 1350 - 1358
  • [26] Comparison of the Efficacy and Safety of Memantal and the Original Drug Memantine in Mild and Moderate Alzheimer’s Disease-Associated Dementia
    Shiryaev O.Y.
    Shapovalov D.L.
    Polozova T.M.
    Goncharova O.V.
    Kuznetsova N.A.
    Cherenkova E.V.
    Fedorova E.Y.
    Neuroscience and Behavioral Physiology, 2017, 47 (7) : 799 - 805
  • [27] Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials
    Farlow M.R.
    Graham S.M.
    Alva G.
    Drug Safety, 2008, 31 (7) : 577 - 585
  • [28] Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease
    Emre, Murat
    Mecocci, Patrizia
    Stender, Karina
    JOURNAL OF ALZHEIMERS DISEASE, 2008, 14 (02) : 193 - 199
  • [29] Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
    Peskind, Elaine R.
    Potkin, Steven G.
    Pomara, Nunzio
    Ott, Brian R.
    Graham, Stephen M.
    Olin, Jason T.
    McDonald, Scott
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (08) : 704 - 715
  • [30] Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study
    Holthoff, Vjera
    Ferris, Steven
    Gauthier, Serge
    Ihl, Ralf
    Robert, Philippe
    Winblad, Bengt
    Sternberg, Kati
    Tennigkeit, Frank
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2013, 28 (02) : 164 - 172
12345